Pfizer Inc. $PFE Shares Bought by Ritholtz Wealth Management

Key Points

• Ritholtz Wealth Management increased its holdings in Pfizer by 71.8% during the second quarter, owning 89,008 shares valued at approximately $2.16 million.
• Pfizer reported $0.78 earnings per share for the last quarter, exceeding estimates and showing a 10.3% revenue increase year-over-year.
• The biopharmaceutical company declared a quarterly dividend of $0.43, with a yield of 7.1%, to be paid on December 1st.

Ritholtz Wealth Management increased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 71.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 89,008 shares of the biopharmaceutical company's stock after purchasing an additional 37,209 shares during the quarter. Ritholtz Wealth Management's holdings in Pfizer were worth $2,158,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of PFE. Brighton Jones LLC raised its holdings in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC raised its holdings in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after acquiring an additional 2,087 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Pfizer by 69.0% during the first quarter. GAMMA Investing LLC now owns 63,131 shares of the biopharmaceutical company's stock valued at $1,600,000 after acquiring an additional 25,785 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Pfizer by 55.3% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 2,606,123 shares of the biopharmaceutical company's stock valued at $66,039,000 after acquiring an additional 928,180 shares during the last quarter. Finally, Shepherd Financial Partners LLC raised its holdings in shares of Pfizer by 3.8% during the first quarter. Shepherd Financial Partners LLC now owns 16,964 shares of the biopharmaceutical company's stock valued at $430,000 after acquiring an additional 617 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Trading Down 0.7%

PFE opened at $24.22 on Friday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.53. The business has a fifty day simple moving average of $24.89 and a 200-day simple moving average of $24.12. The firm has a market cap of $137.70 billion, a P/E ratio of 12.88, a P/E/G ratio of 0.81 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on PFE shares. Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. UBS Group reissued a "neutral" rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Bank of America increased their target price on Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a report on Friday, October 3rd. Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a report on Wednesday, October 8th. Finally, Morgan Stanley dropped their price target on Pfizer from $33.00 to $32.00 and set an "equal weight" rating for the company in a research report on Friday, October 10th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $28.13.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.